Risk factors and efficacy outcomes of early-onset severe neutropenia due to paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab in advanced gastric cancer: a multicenter retrospective cohort study

BACKGROUND: Paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab (PTX/nab-PTX + RAM) is widely used as second-line chemotherapy for advanced gastric cancer (AGC), but severe neutropenia often develops with this regimen. Although previous studies have reported that severe neu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagiwara, Yuya, Nakasya, Akio, Matsumoto, Toshihiko, Ikoma, Tatsuki, Yamamoto, Yoshiyuki, Kurioka, Yusuke, Tsuduki, Takao, Kajiwara, Takeshi, Nishina, Tomohiro, Yamashita, Natsumi, Moriwaki, Toshikazu, Hyodo, Ichinosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830338/
https://www.ncbi.nlm.nih.gov/pubmed/36636083
http://dx.doi.org/10.21037/jgo-22-499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830338/
https://www.ncbi.nlm.nih.gov/pubmed/36636083
http://dx.doi.org/10.21037/jgo-22-499

Ejemplares similares